IDEXX Laboratories, Inc. (IDXX)

Over the past six months, IDEXX Laboratories' stock price has outperformed the S&P 500 Index by +22.53%. As of June 27, 2025, the shares were trading +17.01% higher than their 200-day moving average. Key events impacting the stock price include better-than-anticipated fourth quarter and full year 2024 earnings, robust first quarter 2025 earnings, new product launches, and the dismissal of a consumer lawsuit.

The provided search results do not contain explicit detailed information about the demand seasonality for IDEXX Laboratories, Inc.'s products and services. The company's revenue is significantly driven by its Companion Animal Group (CAG), and the demand for its offerings is expected to rise as pet ownership increases and the focus on livestock and poultry health intensifies. Economic weakness or perceived economic weakness in key geographies could reduce demand for products and services, impacting sales and profitability. Public health issues such as pandemics can also disrupt the supply chain and affect customer demand. The company's recurring revenue model, driven by the placement of diagnostic instruments and the subsequent sale of single-use consumables and tests, suggests a relatively stable demand for these core offerings.

IDEXX Laboratories, Inc. is a global provider of diagnostic and information management-based products and services for the veterinary, water testing, and livestock industries. The company operates within the Healthcare sector, specifically in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry. The company's business is segmented into three primary groups: Companion Animal Group (CAG), Water Quality Products, and Livestock, Poultry, and Dairy (LPD). In the fourth quarter of 2024, IDEXX launched the IDEXX inVue Dx Cellular Analyzer in North America, which utilizes advanced optics and AI technology.

IDEXX Laboratories, Inc. has a significant global presence, operating in approximately 32 countries and maintaining a sales presence in major regions worldwide. The company distributes its products directly and through a network of distributors and resellers across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Approximately 22% of the company's consolidated revenue for 2024 was derived from products manufactured or sourced in U.S. dollars and sold internationally in local currencies.

IDEXX Laboratories has a strong brand reputation for quality and reliability in the veterinary healthcare market. The company is known for innovation in veterinary diagnostics and IT solutions. Integration of AI into products presents technological risks, including potential flaws in AI algorithms and datasets, as well as regulatory challenges. The company relies on the continuous operation and security of its IT systems, and cybersecurity breaches or IT disruptions could adversely affect business operations and reputation. A consumer lawsuit regarding veterinary service prices was largely dismissed in March 2025, which could be seen as a positive resolution for the company's reputation.

IDEXX Laboratories, Inc. has significant institutional ownership, with 91.39% of its stock held by institutional shareholders. As of March 31, 2025, 2018 institutional owners and shareholders had filed 13D/G or 13F forms with the SEC, holding a total of 87,479,894 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual ownership accounts for 1.77% of the company's stock, with Jonathan W. Ayers being the largest individual shareholder.